Jianguo Hong

Jianguo Hong

Auto-generated profile, based on publicly available information

Jianguo Hong

Department of General Surgery, Qilu hospital, Shandong University, Jinan, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ZDZi-Niu Ding
Zi-Niu Ding
GMGuang-Xiao Meng
Guang-Xiao Meng
JXJun-Shuai Xue
Jun-Shuai Xue
LYLun-Jie Yan
Lun-Jie Yan
HLHui Liu
Hui Liu
TLTao Li
Tao Li

19 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
KLKai-Xuan Liu
Kai-Xuan Liu
JHJian-Guo Hong
Jian-Guo Hong
RWRui Wu
Rui Wu
ZDZhao-Ru Dong
Zhao-Ru Dong
YYYa-Fei Yang
Ya-Fei Yang
TLTao Li
Tao Li
Background and Aims: The clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the effect of antiviral treatment prophylaxis on HBV reactivation, overall survival (OS), and postoperative liver function in patients with low preoperative HBV-DNA levels undergoing curative resection.Methods: A meta-analysis was conducted by searching Web of Science, PubMed, Embase, and Cochrane Library until May 2020. We used REVMAN for data analysis and completed the study under the PRISMA guidelines.Results: Three randomized trials and seven cohort studies, comprising of 1,131 individuals, were included in the meta-analysis. Antiviral treatment significantly reduced the rate of HBV reactivation after curative treatment of HCC, with a pooled risk ratio of 0.12 (95% c.i. 0.07 to 0.21; P < 0.00001). The trials were consistently favorable for the antiviral group, with a pooled hazard ratio of 0.52 (95% c.i. 0.37 to 0.74; P = 0.0002) in respect of OS rate. However, by pooling the data from studies that reported ALT on the 30th day postoperatively, the result didn’t reach statistical significance (mean difference −4.38, 95% c.i. −13.83 to 5.07; P = 0.36). The I² values of the heterogeneity test for the above three comparisons are zero.Conclusion: Antiviral therapy during curative resection is effective in reducing HBV reactivation and improving OS rate in HCC patients with low viral load.

17 January 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
LYLun-Jie Yan
Lun-Jie Yan
SYSheng-Yu Yao
Sheng-Yu Yao
HLHai-Chao Li
Hai-Chao Li
GMGuang-Xiao Meng
Guang-Xiao Meng
KLKai-Xuan Liu
Kai-Xuan Liu
TLTao Li
Tao Li
Previous meta-analyses have shown that aspirin use may reduce the risk of hepatocellular carcinoma (HCC). However, the optimal dose, frequency, and duration of aspirin use or the safety and efficacy of aspirin in target populations for HCC prevention remain unclear. The study aim was to investigate the efficacy and safety of aspirin for prevention of HCC.

10 June 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
JHJ Hong
J Hong
KWK Wang
K Wang
YYY Yu
Y Yu

1 April 2019 in Gastroenterology
Verified
Journal Article
Closed access
ZLZhen Li
Zhen Li
KWKangyu Wang
Kangyu Wang
JHJianguo Hong
Jianguo Hong

14 October 2020 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
HZHui Zhang
Hui Zhang
JHJianguo Hong
Jianguo Hong
TLTao Li
Tao Li